Search

Your search keyword '"Azzan, C"' showing total 7 results
Start Over Author "Azzan, C"
7 results on '"Azzan, C"'

1. PF655 PROGNOSTIC RELEVANCE OF THE GENE EXPRESSION SIGNATURE IN PRIMARY AND SECONDARY MYELOFIBROSIS

Author

Rontauroli, S., primary, Zini, R., additional, Bianchi, E., additional, Genovese, E., additional, Carretta, C., additional, Parenti, S., additional, Fantini, S., additional, Mallia, S., additional, Castellano, S., additional, Guglielmelli, P., additional, Pietra, D., additional, Rumi, E., additional, Salmoiraghi, S., additional, Delaini, F., additional, Mora, B., additional, Elli, L., additional, Accetta, R., additional, Villani, L., additional, Azzan, C., additional, Rosti, V., additional, Passamonti, F., additional, Rambaldi, A., additional, Cazzola, M., additional, Vannucchi, A.M., additional, Tagliafico, E., additional, and Manfredini, R., additional

Published
2019
Full Text
View/download PDF

2. Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations

Author

Pennucci, V, Zini, R, Norfo, R, Guglielmelli, P, Bianchi, E, Salati, S, Sacchi, G, Prudente, Z, Tenedini, E, Ruberti, S, Paoli, C, Fanelli, T, Mannarelli, C, Tagliafico, E, Ferrari, S, Vannucchi, Am, Manfredini, R, on behalf of Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators Collaborators Vannucchi AM, Balliu, M, Bartalucci, N, Bogani, C, Bosi, A, Fjerza, R, Martinelli, S, Pancrazzi, A, Pieri, L, Bisognin, Andrea, Bortoluzzi, Stefania, Coppe, Alessandro, Saccoman, Claudia, Masciulli, A, Giovani, B, Azzan, C, Badalucco, S, Balduini, A, Bonetti, E, Campanelli, R, Catarsi, P, Isgrò, Ma, Lupo, Ml, Magrini, U, Massa, M, Poletto, V, Rosti, V, Villani, L, Cazzola, M, Ambaglio, I, Bernasconi, P, Casetti, Ic, Catricalà, S, Elena, C, Fugazza, E, Gallì, A, Malcovati, L, Milanesi, C, Pascutto, C, Pietra, D, Ripamonti, F, Rossi, M, Rumi, E, Dejana, E, Breviario, F, Corada, M, Erba, Bg, Rambaldi, A, Barbui, T, Ferrari, Ml, Finazzi, G, Finazzi, Mc, Gritti, G, Belotti, C, Boroni, C, Salmoiraghi, S, Amaru, A, Golay, J, Cilloni, D, Campia, V, Carturan, S, Guerrasio, A, Montanari, M, and Zini, R.

Subjects
medicine.medical_specialty, Cancer Research, Antigens, CD34, Biology, Transcriptome, Internal medicine, Hematology, Oncology, Gene expression, medicine, Humans, Myelofibrosis, MEG3, Regulation of gene expression, Reverse Transcriptase Polymerase Chain Reaction, RNA, Prognosis, medicine.disease, Gene Expression Regulation, Neoplastic, Primary Myelofibrosis, Cancer cell, Immunology, Cancer research, RNA, Long Noncoding
Abstract

Long non-coding RNAs (lncRNAs), an emerging group of gene expression regulators in normal and cancer cells, are defined as endogenous RNAs consisting of more than 200 nucleotides and lacking an ope...

Published
2015

3. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis

Author

Rumi, E, Pietra, D, Pascutto, C, Guglielmelli, P, Martínez Trillos, A, Casetti, I, Colomer, D, Pieri, L, Pratcorona, M, Rotunno, G, Sant'Antonio, E, Bellini, M, Cavalloni, C, Mannarelli, C, Milanesi, C, Boveri, E, Ferretti, V, Astori, C, Rosti, V, Cervantes, F, Barosi, G, Vannucchi, Am, Cazzola, M, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators Collaborators Vannucchi AM, Balliu, M, Bartalucci, N, Biamonte, F, Bisognin, A, Bogani, C, Bortoluzzi, S, Bosi, A, Coppe, A, Fanelli, T, Fjerza, R, Loiacono, I, Marchioli, R, Martinelli, S, Masciulli, A, Pancrazzi, A, Paoli, C, Saccoman, C, Spolverini, A, Susini, Mc, Tozzi, L, Azzan, C, Badalucco, S, Balduini, A, Bonetti, E, Campanelli, R, Catarsi, P, Isgrò, Am, Lupo, Ml, Magrini, U, Massa, M, Poletto, V, Villani, L, Ambaglio, I, Bernasconi, P, Casetti, Ic, Catricalà, S, Elena, C, Fugazza, E, Gall, A, Malcovati, L, Ripamonti, F, Rossi, M, Dejana, E, Breviario, F, Corada, M, Erba, Bg, Rambaldi, A, Amaru, A, Barbui, T, Belotti, C, Boroni, C, Ferrari, Ml, Finazzi, G, Finazzi, Mc, Golay, J, Gritti, G, Salmoiraghi, S, Cilloni, Daniela, Campia, V, Carturan, S, Guerrasio, Angelo, Manfredini, R, Bianchi, E, Salati, S, Tagliafico, E, Tenedini, E, and Zini, R.

Subjects
Oncology, Male, Clinical Trials and Observations, Leukocytosis, DNA Mutational Analysis, Kaplan-Meier Estimate, Biochemistry, Risk Factors, hemic and lymphatic diseases, Aged, 80 and over, Leukemia, biology, Incidence (epidemiology), food and beverages, Anemia, Hematology, Middle Aged, Prognosis, Cell Transformation, Neoplastic, Female, medicine.symptom, Receptors, Thrombopoietin, Adult, medicine.medical_specialty, Adolescent, Immunology, Lower risk, Risk Assessment, Young Adult, Internal medicine, medicine, Humans, Myelofibrosis, Aged, Proportional Hazards Models, business.industry, Proportional hazards model, Cell Biology, Janus Kinase 2, medicine.disease, Thrombocytopenia, Primary Myelofibrosis, Mutation, biology.protein, business, Calreticulin
Abstract

We studied the impact of driver mutations of JAK2, CALR, (calreticulin gene) or MPL on clinical course, leukemic transformation, and survival of patients with primary myelofibrosis (PMF). Of the 617 subjects studied, 399 (64.7%) carried JAK2 (V617F), 140 (22.7%) had a CALR exon 9 indel, 25 (4.0%) carried an MPL (W515) mutation, and 53 (8.6%) had nonmutated JAK2, CALR, and MPL (so-called triple-negative PMF). Patients with CALR mutation had a lower risk of developing anemia, thrombocytopenia, and marked leukocytosis compared with other subtypes. They also had a lower risk of thrombosis compared with patients carrying JAK2 (V617F). At the opposite, triple-negative patients had higher incidence of leukemic transformation compared with either CALR-mutant or JAK2-mutant patients. Median overall survival was 17.7 years in CALR-mutant, 9.2 years in JAK2-mutant, 9.1 years in MPL-mutant, and 3.2 years in triple-negative patients. In multivariate analysis corrected for age, CALR-mutant patients had better overall survival than either JAK2-mutant or triple-negative patients. The impact of genetic lesions on survival was independent of current prognostic scoring systems. These observations indicate that driver mutations define distinct disease entities within PMF. Accounting for them is not only relevant to clinical decision-making, but should also be considered in designing clinical trials.

Published
2014

4. RESULTS OF THE IMPLEMENTATION OF THE AIEOP RECOMMENDATIONS FOR AGAMMAGLUBOLINEMIA X-RECESSION (SLA): NATUAL HISTORY AND QUALITY OF LIFE OF 139 PATIENTS WITH XLA

Author

Soresina, A., Rondelli, R., Pulcini, S., Quinti, I., Azzan, C., Pietrogrande, M. C., Martino, S., Mattia, D., Martire, B., Rossi, P., Moschese, V., Cardinale, F., Masi, M., Pignata, C., Cazzola, G. A., Duse, M., Consolini, R., Stabile, A., Locatelli, F., Trizzino, N., Maria Rosaria RICCIARDI, Di Nardo, R., Nespoli, L., Marseglia, G. L., Felici, P., Fionni, M., Giliani, S., Pession, A., Ugazio, A. G., and Plebani, A.

Subjects
Settore MED/38 - Pediatria Generale e Specialistica
Published
2012

5. High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis

Author

Rosti, V, Bonetti, E, Bergamaschi, G, Campanelli, R, Guglielmelli, P, Maestri, M, Magrini, U, Massa, M, Tinelli, C, Viarengo, G, Villani, L, Primignani, M, Vannucchi, Am, Frassoni, F, Barosi, G, Agimm, Investigators, INCLUDING VANNUCCHI AM, Antonioli, E, Bartalucci, N, Biamonte, F, Bogani, C, Bosi, A, Fjerza, R, Malevolti, E, Pancrazzi, A, Pieri, L, Spolverini, A, Susini, Mc, Tozzi, L, Bortoluzzi, Stefania, Bisognin, A, Coppe, A, Marchioli, R, Azzan, C, Badalucco, S, Balduini, A, Carolei, A, Currao, M, Isgrã’, Ma, Lupo, Ml, Magni, V, Cazzola, M, Bernasconi, P, Boggi, S, Elena, C, Gallãœ, A, Malcovati, L, Pascutto, C, Passamonti, F, Pietra, D, Rumi, E, Dejana, E, Corada, M, Giannotta, M, Rambaldi, A, Ferrari, Ml, Finazzi, G, Finazzi, Mc, Magri, M, Quaresmini, G, Montalvo, Ml, Ricci, C, Salmoiraghi, S, Spinelli, O, Amaru, A, Golay, J, Cilloni, D, Arruga, F, Bracco, E, Carturan, S, Gaidano, V, Guerrasio, A, Pradotto, M, Manfredini, R, Bianchi, E, Montanari, M, Salati, S, Tagliafico, E, Tenedini, E, and Zini, R.

Subjects
Male, Pathology, myeloproliferative neoplasm, Gastroenterology, Cohort Studies, Hematologic Cancers and Related Disorders, splanchnic vein thrombosis, Hemoglobins, Polycythemia vera, Molecular Cell Biology, Odds Ratio, Splanchnic Circulation, Polycythemia Vera, Aged, 80 and over, Venous Thrombosis, Thrombocytosis, Likelihood Functions, Multidisciplinary, Hematology, Middle Aged, Venous thrombosis, Oncology, Medicine, Female, Cellular Types, Research Article, Adult, medicine.medical_specialty, Clinical Pathology, Science, Sensitivity and Specificity, Myeloproliferative Disorders, Diagnostic Medicine, Internal medicine, medicine, Humans, Myelofibrosis, Biology, Myeloproliferative neoplasm, Aged, Essential thrombocythemia, business.industry, Endothelial Cells, Cancers and Neoplasms, Odds ratio, medicine.disease, Thrombocytopenia, Cross-Sectional Studies, Splanchnic vein thrombosis, business, Biomarkers, General Pathology
Abstract

Increased mobilization of circulating endothelial progenitor cells may represent a new biological hallmark of myeloproliferative neoplasms. We measured circulating endothelial colony forming cells (ECFCs) in 106 patients with primary myelofibrosis, fibrotic stage, 49 with prefibrotic myelofibrosis, 59 with essential thrombocythemia or polycythemia vera, and 43 normal controls. Levels of ECFC frequency for patient's characteristics were estimated by using logistic regression in univariate and multivariate setting. The sensitivity, specificity, likelihood ratios, and positive predictive value of increased ECFC frequency were calculated for the significantly associated characteristics. Increased frequency of ECFCs resulted independently associated with history of splanchnic vein thrombosis (adjusted odds ratio = 6.61, 95% CI = 2.54-17.16), and a summary measure of non-active disease, i.e. hemoglobin of 13.8 g/dL or lower, white blood cells count of 7.8×10(9)/L or lower, and platelet count of 400×10(9)/L or lower (adjusted odds ratio = 4.43, 95% CI = 1.45-13.49) Thirteen patients with splanchnic vein thrombosis non associated with myeloproliferative neoplasms were recruited as controls. We excluded a causal role of splanchnic vein thrombosis in ECFCs increase, since no control had elevated ECFCs. We concluded that increased frequency of ECFCs represents the biological hallmark of a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. The recognition of this disease category copes with the phenotypic mimicry of myeloproliferative neoplasms. Due to inherent performance limitations of ECFCs assay, there is an urgent need to arrive to an acceptable standardization of ECFC assessment.

Published
2010

7. The Italian registry of myelofibrosis is one year old.

Author

Barosi G, Marchetti M, and Azzan C

Subjects
Humans, Italy epidemiology, Medical Records, Models, Organizational, National Health Programs organization & administration, Primary Myelofibrosis epidemiology, Registries
Published
2000

Catalog

Books, media, physical & digital resources
See catalog results